EURid Q2 2019 Progress Report Now Available
14.8.2019 11:00:00 EEST | Business Wire | Press release
EURid released its Q2 2019 Progress Report today, sharing its quarterly statistics and developments. Highlights include:
- 164 906 new domain name registrations were recorded;
- Ireland tops the list of top growth countries at +18% growth;
- The average renewal rate was 82.3%, up 4% since Q1.
The quarter ended with a total of 3 623 691 .eu registrations. The high increase in Ireland could be related to the notice about UK withdrawal from the EU and its subsequence to UK .eu domain name holders. Some of the UK domain name holders may have had the chance to transfer the domain names to their branches in other countries of the EU and EEA, e.g. the neighboring Ireland.
Q2 confirmed to be strong on renewal rate as the .eu domain name registration was launched in April 2006, that is also the month when the majority of .eu domain names were registered. The renewal rate of Q2 shows that the original registrants continue to rely on their .eu domain names.
Developments throughout the quarter also included:
- EURid and European Commission Service Concession Contract extended until 12 October 2022;
- EURid and EUIPO strengthened their cooperation;
- EURid contributed to the Monchique reforestation in Portugal and the Uganda Borehole projects to offset its CO2 emissions;
- ICANN announced the completion of the string evaluation for the IDN ccTLD “ευ” (xn--qxa6a), .eu in Greek.
Click here for EURid’s Q2 2019 Progress Report.
About EURid
EURid is the not-for-profit organisation that operates the .eu and .ею top-level domains, following a tender process and appointment by the European Commission. EURid works with over 700 accredited registrars and provides support in the 24 official EU languages. As part of its ongoing commitment to data security, EURid has been certified for the ISO27001 security standard since 2013. EURid is also registered by the EU Eco-Management and Audit Scheme (EMAS), which is an expression of its environmental commitment. EURid has its headquarters in Brussels (Belgium), and regional offices in Pisa (Italy), Prague (the Czech Republic) and Stockholm (Sweden). More information at: www.eurid.eu.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190814005042/en/
Contact information
EURid
Reelika Kirna
press@eurid.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types13.7.2026 11:00:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for patients with von Willebrand disease (VWD). The data are being shared in an oral presentation today at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026 Congress) in Paris. Latarcibart modulates Protein S to improve hemostasis, potentially enhancing the body’s ability to prevent or reduce the frequency of bleeding episodes. Latarcibart is in pivotal Phase 3 development for patients with VWD, the most common inherited bleeding disorder. If approved, latarcibart has the potential to be the first, once monthly subcutaneous prophylactic therapy for patients with VWD, offering an important alternative to the frequent intravenous infusions of replacement factor concentrates commonly used in the prophylactic setting today. Gi
Europe’s Demand for Tech Services Accelerates in Q2, As Spending on AI and Managed Services Rises: ISG Index™13.7.2026 11:00:00 EEST | Press release
Demand for technology services in Europe continued to accelerate in the second quarter, as the region increasingly turns to managed services to reduce costs and cloud services to meet AI objectives, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows second-quarter ACV for the combined market (both managed services and cloud-based as-a-service) soared 46 percent—its largest growth in eight years—to US $13.0 billion. The latest quarter adds to a string of three straight quarters in which growth has averaged 33 percent. “Europe has become the fastest-growing region for technology services, fueled not only by an increasing demand for AI, but for managed services, which acts as a cost-savings lever to help fund AI ambitions and continued digital
Maureen Mahr von Staszewski Joins Heitman European Leadership Team13.7.2026 10:30:00 EEST | Press release
Heitman LLC (“Heitman”), a global real estate investment management firm, today announced the appointment of Maureen Mahr von Staszewski as Managing Director in the firm’s European Real Estate Investment team. As part of Heitman’s European leadership team, Maureen will help drive continued expansion across Europe, supporting the firm’s strategic growth initiatives, capital raising efforts, and investment activity across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713202147/en/ Maureen Mahr von Staszewski Joins Heitman European Leadership Team “We are excited Maureen has joined the Heitman team,” said Caleb Mercer, Managing Director and Head of European Investment at Heitman. “Her breadth and depth of experience in European real estate investment management will help strengthen our innovative and differentiated investment capabilities across traditional and alternative property types throughout Europe.” In h
LTM Partners with Anthropic to Accelerate Claude Adoption and Expand Enterprise Delivery13.7.2026 09:16:00 EEST | Press release
LTM, the Business Creativity partner to the world's largest enterprises, today announced a partnership with Anthropic, the frontier AI company behind Claude, to accelerate enterprise-scale adoption of Claude, Claude Code and Claude Cowork across engineering, modernization, and business workflows. LTM will combine Claude, Claude Code and Claude Cowork with its enterprise implementation expertise to help clients move from pilots to production with market-leading productivity, throughput, quality underscored by assurance and transparency. LTM will specifically bring this expertise and capability to BFSI, Hi-Tech, Consumer and Production Industry domains. The three strategic focus areas of partnership include: LTM BlueVerse™: AI Delivery Fabric LTM BlueVerse AI Delivery Fabric will serve as the enterprise implementation layer for Claude adoption, integrating Claude and Claude Code into delivery workflows across AI-led software engineering, application modernization, agent orchestration, Si
Sofinnova Partners Appoints David Evans as Partner13.7.2026 09:00:00 EEST | Press release
Sofinnova Partners ("Sofinnova"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of David Evans as Partner. A physician-scientist with deep pharma and drug development expertise, Evans joins from the Roche Venture Fund, where he most recently served as Senior Investment Director. His career spans frontline patient care as a doctor in Australia and with Médecins Sans Frontières, health policy and financing at the World Bank, and roles across the pharmaceutical industry in health economics & outcomes research and drug development before moving into life-sciences investing. Evans’s breadth of experience, anchored in hands-on pharma expertise, contributes complementary expertise to Sofinnova's Crossover Strategy. Evans will play a key role in the Strategy’s late-stage private and public life-sciences investments. His combination of clinical, scientific, and investment expertise strengthens the firm's ability to evaluat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom